IFAN Financial, Inc.

IFAN

US45173B1017

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 10:39:35 2024-05-07 am EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		0.00%	-75.00%

2023	IFAN Financial, Inc. announced that it expects to receive $0.124 million in funding	CI
2019	IFAN Financial, Inc. cancelled the transaction announced on April 21, 2016	CI

IFAN Financial, Inc. Announces Audited Consolidated Earnings Results for the Full Year Ended August 31, 2014

February 24, 2015 at 05:11 pm EST

IFAN Financial, Inc. announced audited consolidated earnings results for the full year ended August 31, 2014. For the year, the company reported interest income of $1,000 compared to $0 a year ago. Net loss was $41,798 compared to $19,209 a year ago.

Net loss attributable to common shareholders $1,791,959 compared to $19,209 a year ago. Net cash used in operating activities was $92,493 compared to $9,885 a year ago.

Latest news about IFAN Financial, Inc.

IFAN Financial, Inc. announced that it expects to receive $0.124 million in funding	23-03-23	CI
IFAN Financial, Inc. cancelled the transaction announced on April 21, 2016	19-04-20	CI
IFAN Financial, Inc. announced that it has received $0.1 million in funding	17-04-30	CI
IFAN Financial, Inc. Accepts Resignation of Jason Aplin as Vice President and Director	16-12-29	CI
IFAN Financial, Inc. cancelled the transaction announced on May 14, 2015	16-11-13	CI
IFAN Financial, Inc. will Change its Ticker to IFAN from IFANE	16-04-29	CI
IFAN Financial, Inc. announced that it expects to receive $10 million in funding from Old Main Capital	16-04-20	CI
IFAN Financial, Inc. will Change its Ticker to IFAN from IFANE	16-01-22	CI
IFAN Financial, Inc. Auditor Raises 'Going Concern' Doubt	15-12-14	CI
IFAN Financial Hires Jason Aplin as Vice President of Sales and to Board of Directors	15-11-19	CI
IFAN Financial Inc. Enters into a Strategic Relationship with GTV Corporation	15-06-23	CI
Ken Mayer to Join IFAN Financial, Inc.'s Board of Directors	15-06-23	CI
IFAN Financial, Inc. Announces Closes Funding Agreement with Sea Otter Global Ventures, LLC	15-06-01	CI
Blue Like Neon Selects IFAN Financial, Inc. to Provide Mobile Payments Solutions	15-05-14	CI
IFAN Financial, Inc. announced that it has received $0.25 million in funding from Sea Otter Global Ventures LLC	15-05-13	CI
IFAN Financial, Inc. announced that it expects to receive $2 million in funding from Sea Otter Global Ventures.	15-05-13	CI
IFAN Financial, Inc. has Changed its Ticker to IFAN.E from IFAN	15-04-22	CI
IFAN Financial, Inc. Appoints John De Puy as a Director	15-04-10	CI
IFAN Financial, Inc. Announces Audited Consolidated Earnings Results for the Full Year Ended August 31, 2014	15-02-24	CI
IFAN Financial, Inc. Auditor Raises 'Going Concern' Doubt	14-12-15	CI
Christopher Menya to Join IFAN Financial as Director and Chief Technology Officer	14-11-11	CI
IFAN Financial, Inc. completed the acquisition of Quidme.	14-10-03	CI
Infantly Available, Inc. will Change its Ticker to IFAND from IFAN	14-09-03	CI
Infantly Available, Inc. will Change its Name to IFAN Financial, Inc	14-09-03	CI
IFAN Financial, Inc. entered into a share exchange agreement to acquire Quidme.	14-07-21	CI

Chart IFAN Financial, Inc.

Duration

Period

More charts

Company Profile

Palantir Bioceuticals, Inc., formerly IFAN Financial, Inc., is a biopharmaceutical company offering holistic solutions to mental health illnesses. The Company uses psychedelic-assisted psychotherapy (PAP), supervised use of ketamine, 3,4-Methylenedioxymethamphetamine (MDMA), psilocybin, Lysergic acid diethylamide (LSD), and ibogaine as part of elaborated psychotherapy programs.

Sector

Pharmaceuticals

More about the company